Abstract
Background
Pre- and postablation atrial fibrillation (AF) brain natriuretic peptide (BNP) levels were shown to predict increased recurrence of AF following ablation.
Objective
Our objective was to assess whether elevated BNP levels merely represent the presence of AF at the time of measurement or indeed the true recurrence of AF.
Methods and Results
In a prospective study of 88 patients undergoing AF ablation, BNP levels were measured immediately before, after, 24 h, and 4–6 months postablation. BNP levels were stratified by presenting rhythm and ventricular rate at the time of measurement. Median BNP level preablation was higher in patients presenting in AF compared to sinus rhythm (SR) (54(44–79) pg/ml vs. 30(18–47) pg/ml, p < 0.001). Postablation restoration of SR in patients presenting in AF reduced median BNP levels from 54(44–79) pg/ml to 40(37–51) pg/ml, (p < 0.001). However, no change was noted in patients who presented in and maintained SR throughout the procedure (30(18–47) pg/ml to 27(16–40) pg/ml, p = 0.270). At 4–6 months, BNP measured in patients in SR was not significantly different from postablation BNP (35(22–53) pg/ml vs. 38(20–52) pg/ml, p = 0.656), although 35 % of them had AF recurrence in 1-year follow-up. Median BNP level measured in five patients while in atrial arrhythmia was elevated compared to postablation BNP (464(421–464) pg/ml to 37(36–37) pg/ml, p = 0.043). BNP levels and ventricular rates are positively correlated at all times pre- and postablation.
Conclusions
BNP level rises acutely during AF and with rapid ventricular rates. BNP level seems to be a function of atrial rhythm and ventricular rate rather than short- or long-term predictor of AF ablation success.
Similar content being viewed by others
Abbreviations
- BNP:
-
Brain natriuretic peptide
- AF:
-
Atrial fibrillation
- SR:
-
Sinus rhythm
- PVAI:
-
Pulmonary vein antral isolation
- AFL:
-
Atrial flutter
- AAD:
-
Antiarrhythmic drugs
- OSA:
-
Obstructive sleep apnea
- ACEI/ARB:
-
Angiotensin converting enzyme inhibitor/angiotensin receptor blocker
References
Levin, E. R., Gardner, D. G., & Samson, W. K. (1998). Natriuretic peptides. New England Journal of Medicine, 339, 321–328.
Silvet, H., Young-Xu, Y., Walleigh, D., & Ravid, S. (2003). Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. American Journal of Cardiology, 92, 1124–1127.
Tsuchida, K., & Tanabe, K. (2004). Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. Journal of Cardiology, 44, 1–11.
Beck-da-Silva, L., de Bold, A., Fraser, M., Williams, K., & Haddad, H. (2004). Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Canadian Journal of Cardiology, 20, 1245–1248.
Vinch, C. S., Rashkin, J., Logsetty, G., Tighe, D. A., Hill, J. C., Meyer, T. E., et al. (2004). Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology, 102, 188–193.
Ohta, Y., Shimada, T., Yoshitomi, H., Inoue, S., Murakami, Y., Shimizu, H., et al. (2001). Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Canadian Journal of Cardiology, 17, 415–420.
Haissaguerre, M., Jais, P., Shah, D. C., et al. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New England Journal of Medicine, 339, 659–666.
Jais, P., Sanders, P., Hsu, L. F., Hosini, M., & Haissaguerre, M. (2005). Catheter ablation for atrial fibrillation. Heart, 91, 7–9.
Kurosaki, K., Tada, H., Hashimoto, T., Ito, S., Miyaji, K., Naito, S., et al. (2007). Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. Circulation Journal, 71, 313–320.
Date, T., Yamane, T., Inada, K., Matsuo, S., Miyanaga, S., Sugimoto, K., et al. (2006). Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation. Heart, 92, 1623–1627.
Yamada, T., Murakami, Y., Okada, T., Yoshida, N., Toyama, J., Yoshida, Y., et al. (2007). Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation. Europace, 9(9), 770–774.
Yamada, T., Murakami, Y., Okada, T., Yoshida, N., Toyama, J., Yoshida, Y., et al. (2008 Mar). Plasma brain natriuretic peptide level after hybrid therapy with pulmonary vein isolation and antiarrhythmic drugs for atrial fibrillation. International Heart Journal, 49(2), 143–151.
Hussein, A. A., Saliba, W. I., Martin, D. O., Shadman, M., Kanj, M., Bhargava, M., et al. (2011). Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation, 123(19), 2077–2082.
Shin, D. I., Deneke, T., Gorr, E., Anders, H., Buenz, K., Paesler, M., et al. (2009). Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic peptide plasma levels. Indian Pacing Electrophysiology Journal, 9, 241–246.
Hwang, H. J., Son, J. W., Nam, B. H., Joung, B., Lee, B., Kim, J. B., et al. (2009). Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation. Clinical Research in Cardiology, 98, 213–218.
Mohanty, S., Mohanty, P., Di Biase, L., Rong, B., Burkhardt, D., Gallinghouse, J. G., et al. (2011). Baseline B-type natriuretic peptide: a gender-specific predictor of procedure-outcome in atrial fibrillation patients undergoing catheter ablation. Journal of Cardiovascular Electrophysiology, 22(8), 858–865.
McKie, P. M., & Burnett, J. C., Jr. (2005). B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clinic Proceedings, 80, 1029–1036.
Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C., Jr. (2002). Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology, 40, 976–982.
Callahan, T. D., 4th, Di Biase, L., Horton, R., Sanchez, J., Gallinghouse, J. G., & Natale, A. (2009). Catheter ablation of atrial fibrillation. Cardiology Clinics, 27, 163–178.
http://www.biosite.com/products/bnp.aspx. last accessed 4/3/10
Oral, H., Knight, B. P., Ozaydin, M., Tada, H., Chugh, A., Hassan, S., et al. (2002). Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. Journal of the American College of Cardiology, 40, 100–104.
Gerbes, A. L., Dagnino, L., Nguyen, T., & Nemer, M. (1994). Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. Journal of Clinical Endocrinology and Metabolism, 78, 1307–1311.
Wasywich, C. A., Webster, M. W., Richards, A. M., & Stewart, R. A. (2006). Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart disease. American Journal of Cardiology, 97, 1068–1072.
Mukoyama, M., Nakao, K., Saito, Y., Ogawa, Y., Hosoda, K., Suga, S., et al. (1990). Human brain natriuretic peptide, a novel cardiac hormone. Lancet, 335, 801–802.
Inoue, S., Murakami, Y., Sano, K., Katoh, H., & Shimada, T. (2000). Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. Journal of Cardiac Failure, 6, 92–96.
Qi, W. F., Kjekshus, H. F., Klinge, R. F., kjekshus, J. K., & Hall, C. (2000). Cardiac natriuretic peptides and continuously monitored atrial pressures during chronic rapid pacing in pigs. Acta Physiologica Scandinavica, 169, 95–102.
Magioncalda, A., Sartini, M., Costaguta, C., Castellaneta, M., Schenone, E., Tognoni, E., et al. (2008). The utility of assaying the N-terminal of brain natriuretic peptide precursor (NT pro-BNP) to predict the clinical outcome in patients with supraventricular tachyarrhythmias observed and treated in the emergency room. Recenti Progressi in Medicina, 99, 141–145.
Chen, L., Wei, T., Zeng, C., Chen, Q., Shi, Z., & Wang, L. (2005). Effect of radiofrequency catheter ablation on plasma B-type natriuretic peptide. Pacing and Clinical Electrophysiology, 28(3), 200–204.
Vanga, S., Pillarisetti, J., Biria, M., Rajoli, S., Pimentel, R., Lakkireddy, D. (2010). Overcoming Fluid Overload After Atrial Fibrillation Ablation with an Open Irrigated Catheter: Role of Scheduled Diuresis and Electrolyte Replacement. Heart Rhythm Supplement 7:pO-06 58. (Abs)
Li, J., & Wang, L. (2006). B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation. Heart and Vessels, 21, 137–140.
Kim, B. J., Hwang, S. J., Sung, K. C., et al. (2007). Assessment of factors affecting plasma BNP levels in patients with chronic atrial fibrillation and preserved left ventricular systolic function. International Journal of Cardiology, 118, 145–150.
Yamada, T., Murakami, Y., Okada, T., Kim, B. S., Kang, J. H., Lee, M. H., et al. (2006). Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation. American Journal of Cardiology, 97, 1741–1744.
Wazni, O. M., Martin, D. O., Marrouche, N. F., Okamoto, M., Shimizu, T., Toyama, J., et al. (2004). Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation, 110, 124–127.
Conflict of interests
No specific conflict of interests related to the study for any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pillarisetti, J., Reddy, N., Biria, M. et al. Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time?. J Interv Card Electrophysiol 40, 161–168 (2014). https://doi.org/10.1007/s10840-014-9898-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-014-9898-7